Category - Developments

Developments

IntelGenx settles Suboxone patent litigation

All patent litigation between IntelGenx (TSXV:IGX; OTCQX:IGXT), Par Pharmaceutical, Indivior and Indivior UK, and Aquestive Therapeutics (formerly MonoSol Rx) related to Suboxone film has been settled. The accord...

May 14, 2018

Developments

3DS strengthens IP with new patents

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) recently received a patent from the Canadian Intellectual Property office, which protects the company’s IP in the area of cognitive diseases in general and...

May 10, 2018

Developments

China approves Profound Medical’s Sonalleve

The Chinese Food and Drug Administration (CFDA) has approved Profound Medical’s (TSXV:PRN; OTCQX:PRFMF) Sonalleve for the non-invasive treatment of uterine fibroids. Sonalleve is a therapeutic platform that combines...

May 10, 2018

Developments

NanoSphere and Vertical in pact to launch Evolve products in AZ and CA

NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has joined forces with Vertical Companies, the largest fully integrated company in the legal medical cannabis industry, to launch NanoSphere’s Evolve product line in...

May 2, 2018

Developments

FDA committee gives Achaogen mixed review on plazomicin

Achaogen (NASDAQ:AKAO) received a mixed review from an FDA advisory committee on its antibiotic, plazomicin, with a vote in favor of approval for complicated urinary tract infections but against its use in bloodstream...

May 2, 2018

Developments

FDA releases Theratechnologies from EGRIFTA post-approval commitments

The FDA has released Theratechnologies (TSX:TH) from post-approval commitments related to the approval of EGRIFTA. When the FDA approved EGRIFTA in 2010, the agency requested that the company conduct two large safety...

May 1, 2018

Developments

Saniona moving to second part of Phase 2a study in Prader-Willi Syndrome

Closely-held Saniona of Denmark has obtained approval to initiate the second part of its Phase 2a trial for Tesomet in adolescents with Prader-Willi syndrome (PWS), the most common genetic cause of life-threatening...

April 26, 2018

Developments

Adocia and Tonghua Dongbao in insulin strategic alliance in China

Adocia (Euronext Paris:FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced a strategic partnership, giving Tonghua exclusive development and commercialization rights in...

April 26, 2018

Developments

Theratechnologies to seek approval of Trogarzo in Europe

Theratechnologies (TSX:TH) plans to seek regulatory approval from the European Medicines Agency (EMA) for Trogarzo using efficacy and safety data from clinical trials submitted to the FDA. “Based on our discussions, we...

April 24, 2018

Developments

CellAegis inks first distribution deal for autoRIC in Europe

Closely-held CellAegis Devices entered into a definitive agreement with Cardiologic, for the marketing and distribution of its autoRIC device in the UK and Ireland. “This marks the first distribution agreement for the...

April 24, 2018

Category - Developments

Subscribe